Filing Details

Accession Number:
0001127602-14-024951
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-08-07 17:20:02
Reporting Period:
2014-08-05
Filing Date:
2014-08-07
Accepted Time:
2014-08-07 16:20:02
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
318154 Amgen Inc AMGN Biological Products, (No Disgnostic Substances) (2836) 953540776
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1560565 M Cynthia Patton One Amgen Center Drive
Thousand Oaks CA 91320-1799
Svp & Cco No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-08-05 920 $58.43 19,154 No 4 M Direct
Common Stock Acquisiton 2014-08-05 1,724 $54.69 20,878 No 4 M Direct
Common Stock Disposition 2014-08-05 2,644 $127.97 18,234 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Nqso (Right to Buy) Disposition 2014-08-05 920 $0.00 920 $58.43
Common Stock Nqso (Right to Buy) Disposition 2014-08-05 1,724 $0.00 1,724 $54.69
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2013-04-26 2020-04-26 No 4 M Direct
1,777 2013-04-25 2021-04-25 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 234 Indirect 401(k) Plan
Footnotes
  1. The price reported is an average price. The prices ranged from $126.62 to $129.00 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.
  2. These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,000 RSUs which fully vest on 10/28/2014; 508 RSUs which vest in on 4/25/2015; 804 RSUs which vest in two annual installments of 396 on 4/27/2015 and 408 on 4/27/2016; 5,420 RSUs which vest in three installments of 1,788, 1,789 and 1,843 on 10/26/2014, 10/26/2015 and 10/26/2016, respectively; 2,103 RSUs which vest in three installments of 693, 694 and 716 on 1/28/2015, 1/28/2016 and 1/28/2017, respectively; and 1,092 RSUs which vest in two equal installments of 360 on 1/31/2016 and 1/31/2017 and one installment of 372 on 1/31/2018. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
  3. These shares include 284 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
  4. These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.